Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 11.6% – Here’s Why

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s share price shot up 11.6% during mid-day trading on Thursday . The company traded as high as $2.84 and last traded at $2.80. 3,554 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 18,790 shares. The stock had previously closed at $2.51.

Lixte Biotechnology Trading Down 12.1 %

The stock’s 50-day simple moving average is $2.25 and its 200-day simple moving average is $2.03. The stock has a market cap of $5.54 million, a price-to-earnings ratio of -1.42 and a beta of -0.04.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned about 0.56% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission. 5.10% of the stock is owned by institutional investors.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.